Zota Health Care Ltd. · NSE:ZOTA
Zota Health Care — Q3 FY23 Earnings Presentation
28 slides from Zota Health Care's earnings presentation, Feb 16, 2023
Slide 1: Cover letter to NSE: Investor Presentation submission
February 16, 2023 To, The Manager Listing Department, The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 Dear Sir/Madam, Trading Symbol: ZOTA Sub: Investor Presentation Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirem
Slide 2: Q3FY23 Performance Highlights
FEBRUARY 2022 Q3FY23 PERFORMANCE HIGHLIGHTS
Slide 3: Safe Harbour
Safe Harbour 02 zotahealthcare.com This presentation has been prepared by the Zota Health Care Limited (the “Company”) only for information purpose to the stakeholders and does not contain any offer or invitation to subscribe the securities of the Company. No offering of securities shall be made exc
Slide 4: Table of Contents
Table of Contents 04 RESULT HIGHLIGHTS 07 OPERATIONAL METRICS 11 DAVAINDIA 20 BUSINESS OUTLOOK & STRATEGY 24 FINANCIAL SUMMARY
Slide 5: Q3FY23 Result Highlights
1 05 06 Q3FY23 Result Highlights Stand Quarterly Financial Highlights Revenue Break up – Quarterly zotahealthcare.com
Slide 6: Stand Quarterly Financial Highlights
Stand Quarterly Financial Highlights 5 zotahealthcare.com Q-o-Q Y-o-Y Revenues (₹ Lakhs) Gross Profit (%) Revenues (₹ Lakhs) Gross Profit (%) 3,404.82 37.12% 3,093.88 3,857.26 34.21% 39.93% 3,404.82 34.21% Q2-FY23 Q3-FY23 Q2-FY23 Q3-FY23 Q3-FY22 Q3-FY23 Q3-FY22 Q3-FY23 Operating Profit (₹ Lakhs) PAT
Slide 7: Revenue Break up - Quarterly
Revenue Break up- Quar terly 06 zotahealthcare.com Domestic Sales Q3-FY23 Q2-FY23 Q3-FY22 Dava India Sales 3,405 3,857 3,094 Export Sales (SEZ)
Slide 8: FY Result Highlights
2 08 09 FY Result Highlights Stand Profit & Loss Statement – Quarterly Management Commentary zotahealthcare.com
Slide 9: Stand Profit & Loss Statement - Quarterly
Stand Profit & Loss Statement- Quar terly 08 zotahealthcare.com Particulars (Rs Lakhs) Q3FY23 Q2FY23 YoY % QoQ % Q3FY22 Export Sales (SEZ) 380.5 903.9 -49% -58% 739.54 Dava India Sales 1481.8 1217.1 63% 22% 910.38 Domestic Sales 1542.6 1736.3 6% -11% 1452.56 Revenues from Operations 3,404.82 3,857.2
Slide 10: Management Commentary
Management Commentar y 09 zotahealthcare.com 1 3 5 The Company has reported Domestic Sales (including The sales contribution from resilient performance in Dava India sales of Dava India) reported new-age business stood at and Domestic sales, however, an increase of 28% YoY and 55% in Q3FY23 as compa
Slide 11: Management Commentary: Domestic Operations and Exports
Management Commentar y 10 zotahealthcare.com 1 DOMESTIC OPERATIONS 2 EXPORTS Domestic Revenues increased by 2% Exports revenues declined by 58% QoQ and a growth of 28% YoY at ₹ on QoQ basis and 49% YoY at ₹ 3024.32 Lakhs in Q3FY23 supported by 380.5 Lakhs in Q3FY23. healthy performance on both front
Slide 12: Davaindia Generic Pharmacy
3 12 14 Generic Phar macy Davaindia Davaindia Key Figures Davaindia- Generic Pharmacy 16 Davaindia- COCO Stores 17 Operational FOFO Stores 18 Operational COCO Stores 19 Management Commentary zotahealthcare.com
Slide 13: Davaindia Key Figures
Davaindia Key Figures 12 zotahealthcare.com No. of SKU’s New Stores rolled-out 1,702 59 1,692 54 51 1,653 31 1,644 Q4-FY22 Q1-FY23 Q2-FY23 Q3-FY23 Q4-FY22 Q1-FY23 Q2-FY23 Q3-FY23
Slide 14: Davaindia Key Figures: GMV
Davaindia Key Figures 13 zotahealthcare.com Gross Mercantile Value (GMV) Total GMV of Davaindia Stores stood at 2,323 Lakhs during Q3FY23 an increase of 20% QoQ Average Wallet Spend (₹) No. of Customers Served (#) Gross Mercantile Value – GMV (₹ Lakhs) 2326 1843 1929 269 267 254 8,63,741 248 237 159
Slide 15: Davaindia - Generic Pharmacy
Davaindia- Generic Phar macy 14 zotahealthcare.com During the quarter Davaindia has Davaindia has led the revolution Davaindia retail pharmacy stores’ catered to the highest-ever number of of patients opting for generic focus continues to be chronic customer i.e. 8.64 lakhs against 7.59 medicines ag
Slide 16: Davaindia - Generic Pharmacy
Davaindia- Generic Phar macy 15 zotahealthcare.com
Slide 17: Davaindia - COCO Stores
Davaindia- COCO Stores 16 zotahealthcare.com
Slide 18: Operational FOFO Stores
Operational 17 zotahealthcare.com FOFO States Uttar Pradesh No. of Stores 90 Stores Madhya Pradesh Odisha 55 53 Gujarat 45 Maharashtra 40 Haryana 31 West Bengal 28 Delhi 24 Rajasthan 22 Kerala 13 Bihar 13 Tamil Nadu 13 Assam 7 Punjab 6 470 Tripura 6 Jharkhand 5 Operational FOFO stores Uttarakhand 5
Slide 19: Operational COCO Stores
Operational 18 zotahealthcare.com COCO States Maharashtra No. of Stores 21 Stores Gujarat Uttar Pradesh 18 11 Rajasthan 7 Delhi 5 Haryana 4 Madhya Pradesh 1 67 Operational COCO stores as on 31.12.2022 Company Owned Company Operated (COCO) Stores Operated by wholly-owned subsidiary Davaindia Health M
Slide 20: Management Commentary
Management Commentar y 19 zotahealthcare.com Commenting on Q3FY23 financial performance and operational highlights, Management Team of Zota Health Care said, “Q3FY23 has been a challenging quarter on some fronts, to begin with our exports performance took a hit during the quarter on account of distu
Slide 21: Industry Snapshot
4 21 22 Industr y Snapshot Retail Generic Medicine Landscape in India Impact of PMBJP 23 Underpenetrated Generic Medicine Market zotahealthcare.com
Slide 22: Retail Generic Medicine Landscape in India
Retail Generic Medicine Landscape in India 21 zotahealthcare.com To achieve the objective of Objectives Savings to the Strong making available quality generic of PMBJP common man Implementation medicines at affordable prices to • To make available quality • A medicine under • The Product Basket of m
Slide 23: Impact of PMBJP
Impact of PMBJP 22 zotahealthcare.com In the financial year (2019-20), PMBJP has achieved sales of ₹258 crores (at MRP), up to 30-11-2019. This has led to savings of approximately ₹1,800 crores of the common citizens of the country. Growth in number of stores* Growth in turnover* Product basket* Pri
Slide 24: Underpenetrated Generic Medicine Market
Underpenetrated Generic Medicine Market 23 zotahealthcare.com 4 pillars to drive healthcare Branded and generic mix of Indian pharma market (%) 4 As of healthcare Generic GX Branded GX Overall India 8 Accessibility Affordability Awarness Aliments • Setting up of • Higher per • Rising literacy • Grow
Slide 25: Financial Summary
5 25 26 Financial Summary Profit & Loss Statement Balance Sheet & Key Ratios zotahealthcare.com
Slide 26: Profit & Loss Statement
Profit & Loss Statement 25 zotahealthcare.com Particulars (INR Lakhs) FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 Income from Operations 5,646.3 6,473.3 7,158.0 7,785.2 8,562.9 9,511.3 10,684.12 13,153.33 Other Income 1.4 7.7 5.6 151.9 154.5 151.3 125.66 164.56 Total Income 5,647.8 6,481.0 7,163.6 7,937
Slide 27: Balance Sheet & Key Ratios
Balance Sheet & Key Ratios 26 zotahealthcare.com Particulars (INR Lakhs) FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 Share capital 1,196.9 1,436.3 1,436.3 1,436.3 1,754.3 1,754.3 2,456.0 2456.03 2,516.0 Reserves and Surplus 384.2 395.7 707.8 1,262.0 5,223.4 5,138.2 4,426.9 4,181.2 6,621.4 Non-curre
Slide 28: Thank You
Thank You Contact Infor mation M r. Himanshu Zota / M r. Ashvin Variya "ZOTA HOUSE", 2/896, Hira Modi Street, Sagrampura, Surat-395 002 (Gujarat) cszota@zotahealthcare.com www.zotahealthcare.com